EGFR TKIs have a high response rate (60%–70%) in EGFR-mutated cancers [12], while Anaplastic Lymphoma Kinase (ALK) inhibitors have a comparable response rate (60%) in patients with ALK translocations [13]. The gene discussed is ALK; the disease is cancer.